A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity

Author:

Bezzina Clive1,Degtiar Vadim2,Danchenko Natalya3,Maisonobe Pascal3ORCID,Davis Benjamin3,Engmann Emanuel2ORCID,Guyon Elodie3,Lecanuet Sophie3,Whalen John2ORCID

Affiliation:

1. North Staffordshire Rehabilitation Centre, Haywood Hospital, Stoke-on-Trent ST6 7AG, UK

2. Ipsen, Slough SL1 3XE, UK

3. Ipsen, 92100 Boulogne-Billancourt, France

Abstract

Service model changes at the North Staffordshire Rehabilitation Centre (UK) included switching spasticity treatment from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A). This noninterventional, retrospective, longitudinal study (NCT04396704) describes the clinical and economic outcomes in toxin-naive adults with spasticity who received onaBoNT-A (Cohort 1; 2015–2017) or aboBoNT-A (Cohort 2; 2017–2019). Outcomes included Goal Attainment Scale T (GAS-T) score, treatment satisfaction, quality of life (QoL; EQ-5D visual analog scale [VAS] score), and treatment costs. Adverse events were recorded for Cohort 2. Cohort 1 included 60 patients (mean [standard deviation] dose, 206.0 [98.8] U); Cohort 2 included 54 patients (753.7 [457.3] U). Mean (95% confidence interval) GAS-T scores for Cohorts 1 and 2 were 43.1 (39.3–46.9) and 47.8 (43.7–51.9) at Week 6, and 43.2 and 44.3 at Week 12, respectively. In both cohorts most patients were satisfied with treatment. At Week 12, QoL had not changed in Cohort 1 but had improved in Cohort 2 (EQ-5D VAS, −5). Mean estimated per-patient costs (in 2021) for Cohorts 1 and 2 were £315.56 and £249.25, respectively, at Week 6, and £343.20 and £273.21, respectively, at Week 12. Fifteen non–treatment-related serious adverse events and two deaths were recorded. These data may warrant a larger prospective study powered to compare outcomes of aboBoNT-A and onaBoNT-A.

Funder

Ipsen

Publisher

MDPI AG

Subject

Health, Toxicology and Mutagenesis,Toxicology

Reference32 articles.

1. Spasticity: Clinical perceptions, neurological realities and meaningful measurement;Pandyan;Disabil. Rehabil.,2005

2. Perspective of an an international online patient and caregiver community on the burden of spasticity and impact of botulinum neurotoxin therapy: Survey study;Patel;JMIR Public Health Surveill.,2020

3. Royal College of Physicians, The British Society Of Rehabilitation Medicine, The Chartered Society of Physiotherapy, and Association of Chartered Physiotherapists in Neurology and the Royal College of Occupational Therapists (2018). Spasticity in Adults: Management Using Botulinum Toxin National Guidelines, Royal College of Physician. [2nd ed.].

4. Spasticity treatment with botulinum toxin;Ward;Turk. J. Phys. Med. Rehab.,2007

5. Improving the management of post-stroke spasticity: Time for action;Christofi;J. Rehabil. Med. Clin. Commun.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3